FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة البروتيدات

VIP

Vasoactive Intestinal Peptide / Aviptadil

Cognitive & Neuro

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide originally isolated from porcine intestinal tissue that functions as a potent vasodilator, immunomodulator, and neurotransmitter throughout the body. It has gained significant research attention for its potential role in treating Chronic Inflammatory Response Syndrome (CIRS) associated with mold illness, as well as pulmonary arterial hypertension. VIP is typically administered via nasal inhalation in clinical research settings, though injectable forms also exist.

mechanism of action

Endogenous 28-amino-acid neuropeptide with broad physiological roles. Potent vasodilator, bronchodilator, and immunomodulator. Promotes neuronal survival, regulates circadian rhythm via SCN, inhibits NF-kB-mediated inflammation, and modulates gut-brain axis signaling.

Research Protocols

للاستخدام البحثي فقط. ليس مشورة طبية.

Research protocols use 50-200mcg intranasally 1-3 times daily. IV research doses used in ARDS studies were 100-300pmol/kg/min. Subcutaneous protocols not well-established due to rapid degradation.

Research Notes

Clinical Research Status

VIP has been studied extensively in the context of CIRS by Dr. Ritchie Shoemaker and others, with intranasal administration showing improvements in inflammatory markers and pulmonary artery pressures. Research in pulmonary hypertension has demonstrated VIP's ability to reduce pulmonary vascular resistance and improve exercise capacity in small clinical trials. It is not FDA-approved for any indication, and its use remains investigational with ongoing debate about optimal dosing protocols.

Key Published Findings

Studies demonstrate VIP's ability to downregulate inflammatory cytokines including TGF-beta, MMP-9, and complement split products C3a and C4a in CIRS patients. In pulmonary hypertension models, VIP reduces right ventricular systolic pressure and pulmonary vascular remodeling through cAMP-mediated smooth muscle relaxation. Neuroprotective properties have been documented in models of Parkinson's disease and Alzheimer's disease through anti-inflammatory and anti-apoptotic mechanisms.

Safety Profile

VIP is generally well-tolerated at therapeutic doses, with the most common side effects being nasal congestion, flushing, and transient hypotension due to its vasodilatory properties. Diarrhea and abdominal cramping may occur at higher doses, reflecting its original physiological role in gut motility regulation. Caution is warranted in patients with existing hypotension or those on antihypertensive medications due to additive blood pressure lowering effects.

Comparison to Related Compounds

VIP belongs to the secretin/glucagon superfamily and shares structural homology with PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide), though VIP has greater selectivity for VPAC1 and VPAC2 receptors. Unlike synthetic vasodilators, VIP provides combined anti-inflammatory and vasodilatory effects through a single molecular pathway. Compared to other CIRS treatments in the Shoemaker protocol, VIP is typically used as a final-step intervention after other markers have been normalized.

Community Observations

Patients using VIP for CIRS report improvements in fatigue, cognitive function, and respiratory symptoms, often describing it as the final piece in their recovery protocol. Sourcing pharmaceutical-grade VIP remains challenging, and proper cold-chain storage is critical for maintaining peptide stability. Some users report rebound symptoms upon discontinuation, suggesting the need for gradual tapering or ongoing maintenance dosing.

Half Life

~1-2 minutes (IV); ~30 min (intranasal)

Reconstitution

Sterile saline for IV; saline for nasal spray

Storage

Lyophilized

Store at -20C. Extremely sensitive to degradation.

Reconstituted

Prepare fresh. Use within hours of reconstitution.

US Legal Status

Research chemical (in clinical trials for ARDS)

Also Known As

Vasoactive Intestinal PeptideAviptadil

الأسئلة الشائعة

ما هو VIP؟

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide originally isolated from porcine intestinal tissue that functions as a potent vasodilator, immunomodulator, and neurotransmitter throughout the body. It has gained significant research attention for its potential role in treating Chronic Inflammatory Response Syndrome (CIRS) associated with mold illness, as well as pulmonary arterial hypertension. VIP is typically administered via nasal inhalation in clinical research settings, though injectable forms also exist.

كيف يعمل VIP؟

Endogenous 28-amino-acid neuropeptide with broad physiological roles. Potent vasodilator, bronchodilator, and immunomodulator. Promotes neuronal survival, regulates circadian rhythm via SCN, inhibits NF-kB-mediated inflammation, and modulates gut-brain axis signaling.

ما هو الوضع التنظيمي لـ VIP في الولايات المتحدة؟

Research chemical (in clinical trials for ARDS)

ما هو عمر النصف لـ VIP؟

~1-2 minutes (IV); ~30 min (intranasal)

ما الأسماء الأخرى لـ VIP؟

Vasoactive Intestinal Peptide, Aviptadil

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer